Trial
NCT07195617
Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment
UnknownWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Guangzhou Bio-gene Technology Co., Ltd
Collaborators
Jiangsu Provincial People's Hospital
Condition
Relapsed/Refractory Multiple Myeloma
Intervention
BCMA-GPRC5D CART
Why stopped
Due to corporate strategic adjustment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-28